Premium
Serum tryptase levels in adverse drug reactions
Author(s) -
Ordoqui E.,
Zubeldia J. M.,
Aranzábal A.,
Rubio M.,
Herrero T.,
Tornero P.,
Rodríguez V. M.,
Prieto A.,
Baeza M. L.
Publication year - 1997
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/j.1398-9995.1997.tb00182.x
Subject(s) - tryptase , anaphylaxis , medicine , drug , allergy , mast cell , drug allergy , immunology , adverse effect , placebo , gastroenterology , anaphylactic reactions , pharmacology , pathology , alternative medicine
We evaluated the usefulness of individual tryptase levels and variations after adverse drug reactions in 64 patients. Our aim was to find a tool for the diagnosis of drug allergy. Thirty‐seven subjects were confirmed to have drug allergy, 12 had nonsteroidal anti‐inflammatory drug (NSAID) reactions, five had negative controlled drug challenges (NAAR), and 10 had symptoms after placebo intake (PLA). Serum tryptase levels greatly increased after anaphylactic shocks (2242%) and anaphylaxis (710.5%). Patients with allergic urticaria and those with idiosyncratic responses to acetylsalicylic acid (ASA) exhibited a small increase in serum tryptase (49.5% and 38.2%, respectively). In the other two groups (NAAR and PLA), no variation in this serum protease was observed. The time of appearance of the serum tryptase peak differed considerably among patients with similar clinical reactions (from 30 min to 6 h) and was independent of the latent period, severity of symptoms, or the amount of tryptase released. We conclude that serum tryptase determinations are helpful in the diagnosis of anaphylactic shock and anaphylaxis, but serial measurements may be needed to confirm mast‐cell participation in milder reactions.